Phage display and molecular imaging: Expanding fields of vision in living subjects

Biotechnology and Genetic Engineering Reviews

Volumn 27, Issue 1, 2010, Pages 57-94

  Cochran, Frank V ^a   Cochran, Jennifer R ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS;

BINDING AGENT; BIOLOGICAL PROCESS; IMAGING AGENT; IMAGING PROBE; IN-VIVO; IN-VIVO IMAGING; MOLECULAR TARGETS; PHAGE-DISPLAY; RESEARCH PROGRAMS; VIVO APPLICATIONS;

MOLECULAR IMAGING;

POLYPEPTIDE;

GENE TECHNOLOGY; HUMAN; MOLECULAR IMAGING; NONHUMAN; PEPTIDE ANALYSIS; PHAGE DISPLAY; PROTEIN ANALYSIS; REPORTER GENE; REVIEW;

EID: 79551608208     PISSN: 02648725     EISSN: 20465556     Source Type: Journal    
DOI: 10.1080/02648725.2010.10648145     Document Type: Article

References (182)

1. Ahlgren, S., Orlova, A., Rosik, D., Sandstrom, M., Sjoberg, A., Baastrup, B., Widmark, O., Fant, G., Feldwisch, J., and Tolmachev, V., 2008. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjugate Chemistry, 19:235–243.
2. Aina, O.H., Liu, R., Sutcliffe, J.L., Marik, J., Pan, C.X., and Lam, K.S., 2007. From combinatorial chemistry to cancer-targeting peptides. Molecular Pharmaceutics, 4:631–651.
3. Arap, W., Kolonin, M., Trepel, M., Lahdenranta, J., Cardo-Vila, M., Giordano, R., Mintz, P.J., Ardelt, P.U., Yao, V.J., Vidal, C.I., Chen, L., Flamm, A., Valtanen, H., Weavind, L.M., Hicks, M.E., Pollock, R.E., Botz, G.H., Bucana, C.D., Koivunen, E., Cahill, D., Troncoso, P., Baggerly, K.A., Pentz, R.D., Do, K.A., Logothetis, C.J., and Pasqualini, R., 2002. Steps toward mapping the human vasculature by phage display. Nature Medicine, 8:121–127.
4. Baum, R.P., Orlova, A., Tolmachev, V., and Feldwisch, J., 2006. A novel molecular imaging agent for diagnosis of recurrent HER2 positive breast cancer. First time in human study using an Indium-111- or Gallium-68-labeled Affibody molecule. European Journal of Nuclear Medicine and Molecular Imaging, 33 (14):S91
5. 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. Journal of Nuclear Medicine, 47:1707–1716.
6. Bjorklund, M., Valtanen, H., Savilahti, H., and Koivunen, E., 2003. Use of inteindirected peptide biosynthesis to improve serum stability and bioactivity of a gelatinase inhibitory peptide. Combinatorial Chemistry and High Throughput Screening, 6:29–35.
7. Brammer, L.A., Bolduc, B., Kass, J.L., Felice, K.M., Noren, C.J., and Hall, M.F., 2008. A target-unrelated peptide in an M13 phage display library traced to an advantageous mutation in the gene II ribosome-binding site. Analytical Biochemistry, 373:88–98.
8. 90Y-DOTA-Biotin. Journal of Nuclear Medicine, 41:131–140.
9. Brinckerhoff, L.H., Kalashnikov, V.V., Thompson, L.W., Yamshchikov, G.V., Pierce, R.A., Galavotti, H.S., Engelhard, V.H., and Slingluff, C.L., Jr. 1999. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27–35) peptide:implications for peptide vaccines. International Journal of Cancer, 83:326–334.
10. Brown, C., Modzelewski, R., Johnson, C., and Wong, M., 2000. A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Annals of Surgical Oncology, 7:743–749.
11. Cai, W., Niu, G., and Chen, X., 2008. Imaging of integrins as biomarkers for tumor angiogenesis. Current Pharmaceutical Design, 14:2943–2973.
12. Cardo-Vila, M., Zurita, A., Giordano, R., Sun, J., Rangel, R., Guzman-Rojas, L., Anobom, C., Valente, A., Almeida, F.C., Lahdenranta, J., Kolonin, M., Arap, W., and Pasqualini, R., 2008. A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11. PLoS ONE, 3:e3452
13. Chen, I., Choi, Y., and Ting, A., 2007. Phage display evolution of a peptide substrate for yeast biotin ligase and application to two-color quantum dot labeling of cell surface proteins. Journal of the American Chemical Society, 129:6619–6625.
14. Chen, L., Zurita, A., Ardelt, P.U., Giordano, R., Arap, W., and Pasqualini, R., 2004a. Design and validation of a bifunctional ligand display system for receptor targeting. Chemistry & Biology, 11:1081–1091.
15. 3-integrin expression. Journal of Nuclear Medicine, 45:1776–1783.
16. 18F-labeled protein scaffold molecules. Journal of Nuclear Medicine, 49:804–813.
17. Clackson, T., and Lowman, H.B., eds. 2004. Phage Display:A Practical Approach, New York:Oxford University Press.
18. Daugherty, P.S., 2007. Protein engineering with bacterial display. Current Opinion in Structural Biology, 17:474–480.
19. Decuzzi, P., Pasqualini, R., Arap, W., and Ferrari, M., 2009. Intravascular delivery of particulate systems:does geometry really matter?. Pharmaceutical Research, 26:235–243.
20. Desai, M.Y., and Schoenhagen, P., 2009. Emergence of targeted molecular imaging in atherosclerotic cardiovascular disease. Expert review of cardiovascular therapy, 7:197–203.
21. 111In-labeled galectin-3 binding peptide in prostate carcinoma. Nuclear Medicine and Biology, 36:137–146.
22. Doronina, S.O., Bovee, T.D., Meyer, D.W., Miyamoto, J.B., Anderson, M.E., Morris-Tilden, C.A., and Senter, P.D., 2008. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjugate Chemistry, 19:1960–1963.
23. Edgar, R., McKinstry, M., Hwang, J., Oppenheim, A.B., Fekete, R.A., Giulian, G., Merril, C., Nagashima, K., and Adhya, S., 2006. High-sensitivity bacterial detection using biotin-tagged phage and quantum-dot nanocomplexes. Proceedings of the National Academy of Sciences of the United States of America, 103:4841–4845.
24. 99mTc-labelled Affibody molecules with reduced renal uptake. European Journal of Nuclear Medicine and Molecular Imaging, 35:2245–2255.
25. 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. Bioorganic and Medicinal Chemistry Letters, 19:3912–3914.
26. Fagerlund, A., Myrset, A., and Kulseth, M., 2008. Construction and characterization of a 9-mer phage display pVIII-library with regulated peptide density. Applied Microbiology and Biotechnology, 80:925–936.
27. Franc, B.L., Acton, P.D., Mari, C., and Hasegawa, B.H., 2008. Small-animal SPECT and SPECT/CT:Important tools for preclinical investigation. Journal of Nuclear Medicine, 49:1651–1663.
28. Friedman, M., Nordberg, E., Hoiden-Guthenberg, I., Brismar, H., Adams, G.P., Nilsson, F.Y., Carlsson, J., and Stahl, S., 2007. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Engineering, Design and Selection, 20:189–199.
29. Friedman, M., Orlova, A., Johansson, E., Eriksson, T.L., Hoiden-Guthenberg, I., Tolmachev, V., Nilsson, F.Y., and Stahl, S., 2008. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. Journal of Molecular Biology, 376:1388–1402.
30. Friedman, M., and Stahl, S., 2009a. Engineered affinity proteins for tumour-targeting applications. Biotechnology and Applied Biochemistry, 53:1–29.
31. Friedman, M., Lindstrom, S., Ekerljung, L., Andersson-Svahn, H., Carlsson, J., Brismar, H., Gedda, L., Frejd, F.Y., and Stahl, S., 2009b. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule. Biotechnology and Applied Biochemistry, 54:121–131.
32. Gai, S.A., and Wittrup, K.D., 2007. Yeast surface display for protein engineering and characterization. Current Opinion in Structural Biology, 17:467–473.
33. Gambhir, S.S., 2002. Molecular imaging of cancer with positron emission tomography. Nature Reviews Cancer, 2:683–693.
34. Giordano, R.J., Cardo-Vila, M., Lahdenranta, J., Pasqualini, R., and Arap, W., 2001. Biopanning and rapid analysis of selective interactive ligands. Nature Medicine, 7:1249–1253.
35. Goodson, R.J., Doyle, M.V., Kaufman, S.E., and Rosenberg, S., 1994. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proceedings of the National Academy of Sciences of the United States of America, 91:7129–7133.
36. Hajitou, A., Lev, D.C., Hannay, J.A., Korchin, B., Staquicini, F.I., Soghomonyan, S., Alauddin, M.M., Benjamin, R.S., Pollock, R.E., Gelovani, J.G., Pasqualini, R., and Arap, W., 2008. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proceedings of the National Academy of Sciences of the United States of America, 105:4471–4476.
37. Hajitou, A., Rangel, R., Trepel, M., Soghomonyan, S., Gelovani, J.G., Alauddin, M.M., Pasqualini, R., and Arap, W., 2007. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nature Protocols, 2:523–531.
38. Hajitou, A., Trepel, M., Lilley, C. E., Soghomonyan, S., Alauddin, M. M., Marini, F. C., Restel, B. H., Ozawa, M. G., Moya, C. A., Rangel, R., Sun, Y., Zaoui, K., Schmidt, M., von Kalle, C., Weitzman, M. D., Gelovani, J. G., Pasqualini, R., and Arap, W., 2006. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell, 125:385–398.
39. Han, Z., Fu, A., Wang, H., Diaz, R., Geng, L., Onishko, H., and Hallahan, D., 2008. Noninvasive assessment of cancer response to therapy. Nature Medicine, 14:343–349.
40. Hanaoka, H., Mukai, T., Habashita, S., Asano, D., Ogawa, K., Kuroda, Y., Akizawa, H., Iida, Y., Endo, K., Saga, T., and Saji, H., 2007. Chemical design of a radiolabeled gelatinase inhibitor peptide for the imaging of gelatinase activity in tumors. Nuclear Medicine and Biology, 34:503–510.
41. Hao, J., Serohijos, A.W., Newton, G., Tassone, G., Wang, Z., Sgroi, D., Dokholyan, N., and Basilion, J., 2008. Identification and rational redesign of peptide ligands to CRIP1, a novel biomarker for cancers. PLoS Computational Biology, 4:e1000138
42. 3-integrin imaging:a new approach to characterise angiogenesis?. European Journal of Nuclear Medicine and Molecular Imaging, 33 (1):S54–S63.
43. Hilderbrand, S.A., Kelly, K.A., Niedre, M., and Weissleder, R., 2008. Near infrared fluorescence-based bacteriophage particles for ratiometric pH imaging. Bioconjugate Chemistry, 19:1635–1639.
44. Hilderbrand, S.A., Kelly, K.A., Weissleder, R., and Tung, C.H., 2005. Monofunctional near-infrared fluorochromes for imaging applications. Bioconjugate Chemistry, 16:1275–1281.
45. Hoogenboom, H., 2005. Selecting and screening recombinant antibody libraries. Nature Biotechnology, 23:1105–1116.
46. Hsiung, P.L., Hardy, J., Friedland, S., Soetikno, R., Du, C., Wu, A., Sahbaie, P., Crawford, J., Lowe, A., Contag, C., and Wang, T., 2008. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nature Medicine, 14:454–458.
47. Imai, S., Mukai, Y., Takeda, T., Abe, Y., Nagano, K., Kamada, H., Nakagawa, S., Tsunoda, S., and Tsutsumi, Y., 2008. Effect of protein properties on display efficiency using the M13 phage display system. Pharmazie, 63:760–764.
48. Jakobovits, A., Amado, R.G., Yang, X., Roskos, L., and Schwab, G., 2007. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nature Biotechnology, 25:1134–1143.
49. Jaye, D.L., Geigerman, C.M., Fuller, R.E., Akyildiz, A., and Parkos, C.A., 2004. Direct fluorochrome labeling of phage display library clones for studying binding specificities:applications in flow cytometry and fluorescence microscopy. Journal of Immunological Methods, 295:119–127.
50. Karasseva, N.G., Glinsky, V.V., Chen, N.X., Komatireddy, R., and Quinn, T.P., 2002. Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. Journal of Protein Chemistry, 21:287–296.
51. Kehoe, J.W., and Kay, B.K., 2005. Filamentous phage display in the new millennium. Chemical Reviews, 105:4056–4072.
52. Kelly, K., Alencar, H., Funovics, M., Mahmood, U., and Weissleder, R., 2004. Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide. Cancer Research, 64:6247–6251.
53. Kelly, K.A., Allport, J.R., Tsourkas, A., Shinde-Patil, V.R., Josephson, L., and Weissleder, R., 2005. Detection of Vascular Adhesion Molecule-1 expression using a novel multimodal nanoparticle. Circulation Research, 96:327–336.
54. Kelly, K.A., Bardeesy, N., Anbazhagan, R., Gurumurthy, S., Berger, J., Alencar, H., Depinho, R., Mahmood, U., and Weissleder, R., 2008a. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Medicine, 5:e85
55. Kelly, K.A., Carson, J., McCarthy, J.R., and Weissleder, R., 2007. Novel peptide sequence (“IQ-tag”) with high affinity for NIR fluorochromes allows protein and cell specific labeling for in vivo imaging. PLoS ONE, 2:e665
56. Kelly, K.A., Clemons, P.A., Yu, A.M., and Weissleder, R., 2006a. High-throughput identification of phage-derived imaging agents. Molecular Imaging, 5:24–30.
57. Kelly, K.A., and Jones, D.A., 2003. Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia, 5:437–444.
58. Kelly, K.A., Nahrendorf, M., Yu, A. M., Reynolds, F., and Weissleder, R., 2006b. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Molecular Imaging and Biology, 8:201–207.
59. Kelly, K.A., Setlur, S.R., Ross, R., Anbazhagan, R., Waterman, P., Rubin, M.A., and Weissleder, R., 2008b. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Research, 68:2286–2291.
60. Kelly, K.A., Waterman, P., and Weissleder, R., 2006c. In vivo imaging of molecularly targeted phage. Neoplasia, 8:1011–1018.
61. Kiesewetter, D.O., Kramer-Marek, G., Ma, Y., and Capala, J., 2008. Radiolabeling of HER2-specific Affibody molecule with F-18. Journal of Fluorine Chemistry, 129:799–806.
62. Kimura, R.H., Cheng, Z., Gambhir, S.S., and Cochran, J.R., 2009a. Engineered knottin peptides:a new class of agents for imaging integrin expression in living subjects. Cancer Research, 69:2435–2442.
63. 1 integrins with low-nanomolar affinity. Proteins:Structure, Function, and Bioinformatics, 77:359–369.
64. Koide, S., and Sidhu, S.S., 2009. The importance of being tyrosine:lessons in molecular recognition from minimalist synthetic binding proteins. ACS Chemical Biology, 4:325–334.
65. Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O.P., Heikkila, P., Kantor, C., Gahmberg, C.G., Salo, T., Konttinen, Y.T., Sorsa, T., Ruoslahti, E., and Pasqualini, R., 1999. Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnology, 17:768–774.
66. Kolonin, M., Pasqualini, R., and Arap, W., 2001. Molecular addresses in blood vessels as targets for therapy. Current Opinion in Chemical Biology, 5:308–313.
67. Krag, D.N., Shukla, G.S., Shen, G.P., Pero, S., Ashikaga, T., Fuller, S., Weaver, D.L., Burdette-Radoux, S., and Thomas, C., 2006. Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Research, 66:7724–7733.
68. Kronqvist, N., Lofblom, J., Jonsson, A., Wernerus, H., and Stahl, S., 2008. A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Protein Engineering, Design and Selection, 21:247–255.
69. Krumpe, L., and Mori, T., 2006a. The use of phage-displayed peptide libraries to develop tumor-targeting drugs. International Journal of Peptide Research and Therapeutics, 12:79–91.
70. Krumpe, L.R.H., Atkinson, A.J., Smythers, G.W., Kandel, A., Schumacher, K.M., McMahon, J.B., Makowski, L., and Mori, T., 2006b. T7 lytic phage-displayed peptide libraries exhibit less sequence bias than M13 filamentous phage-displayed peptide libraries. Proteomics, 6:4210–4222.
71. Kuhnast, B., Bodenstein, C., Haubner, R., Wester, H.J., Senekowitsch-Schmidtke, R., Schwaiger, M., and Weber, W.A., 2004. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nuclear Medicine and Biology, 31:337–344.
72. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors. Journal of Nuclear Medicine, 49:796–803.
73. 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor-expressing breast carcinomas. Clinical Cancer Research, 13:6070–6079.
74. Kuzmicheva, G.A., Jayanna, P.K., Sorokulova, I.B., and Petrenko, V.A., 2009. Diversity and censoring of landscape phage libraries. Protein Engineering, Design and Selection, 22:9–18.
75. Lamboy, J., Tam, P., Lee, L., Jackson, P., Avrantinis, S., Lee, H., Corn, R., and Weiss, G., 2008. Chemical and genetic wrappers for improved phage and RNA display. ChemBioChem, 9:2846–2852.
76. Landon, L., and Deutscher, S., 2003. Combinatorial discovery of tumor targeting peptides using phage display. Journal of Cellular Biochemistry, 90:509–517.
77. Landon, L., Harden, W., Illy, C., and Deutscher, S., 2004a. High-throughput fluorescence spectroscopic analysis of affinity of peptides displayed on bacteriophage. Analytical Biochemistry, 331:60–67.
78. Landon, L., Zou, J., and Deutscher, S., 2004b. Is phage display technology on target for developing peptide-based cancer drugs?. Current drug discovery technologies, 1:113–132.
79. Larbanoix, L., Burtea, C., Laurent, S., Van Leuven, F., Toubeau, G., Elst, L., and Muller, R., 2008. Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiology of Aging, In press
80. Laumonier, C., Segers, J., Laurent, S., Michel, A., Coppee, F., Belayew, A., Elst, L.V., and Muller, R.N., 2006. A new peptidic vector for molecular imaging of apoptosis, identified by phage display technology. Journal of Biomolecular Screening, 11:537–545.
81. Lee, S., and Chen, X., 2009. Dual-modality probes for in vivo molecular imaging. Molecular Imaging, 8:87–100.
82. Lee, S., Hassan, M., Fisher, R., Chertov, O., Chernomordik, V., Kramer-Marek, G., Gandjbakhche, A., and Capala, J., 2008. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clinical Cancer Research, 14:3840–3849.
83. Lendel, C., Dogan, J., and Hard, T., 2006. Structural basis for molecular recognition in an affibody:affibody complex. Journal of Molecular Biology, 359:1293–1304.
84. Li, P., and Roller, P.P., 2002. Cyclization strategies in peptide derived drug design. Current Topics in Medicinal Chemistry, 2:325–341.
85. 64Cu-labeled linear peptide antagonist by microPET. Clinical Cancer Research, 14:4758–4766.
86. Lipovsek, D., and Pluckthun, A., 2004. In-vitro protein evolution by ribosome display and mRNA display. Journal of Immunological Methods, 290:51–67.
87. Liu, C.C., Mack, A.V., Tsao, M.L., Mills, J.H., Lee, H.S., Choe, H., Farzan, M., Schultz, P.G., and Smider, V.V., 2008. Protein evolution with an expanded genetic code. Proceedings of the National Academy of Sciences of the United States of America, 105:17688–17693.
88. Liu, C.M., Jin, Q., Sutton, A., and Chen, L., 2005. A novel fluorescent probe:europium complex hybridized T7 phage. Bioconjugate Chemistry, 16:1054–1057.
89. 3 targeted radiotracers for tumor imaging. Molecular Pharmaceutics, 3:472–487.
90. Liu, Y., Adams, J., Turner, K., Cochran, F.V., Gambhir, S.S., and Soh, H.T., 2009. Controlling the selection stringency of phage display using a microfluidic device. Lab on a Chip, 9:1033–1036.
91. Lonberg, N., 2008. Fully human antibodies from transgenic mouse and phage display platforms. Current Opinion in Immunology, 20:450–459.
92. Magee, J.A., Araki, T., Patil, S., Ehrig, T., True, L., Humphrey, P.A., Catalona, W.J., Watson, M.A., and Milbrandt, J., 2001. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Research, 61:5692–5696.
93. Mao, C., Liu, A., and Cao, B., 2009. Virus-based chemical and biological sensing. Angewandte Chemie International Edition, 48:6790–6810.
94. Marks, K.M., Rosinov, M., and Nolan, G.P., 2004. In vivo targeting of organic calcium sensors via genetically selected peptides. Chemistry and Biology, 11:347–356.
95. Mather, S., 2009. Molecular imaging with bioconjugates in mouse models of cancer. Bioconjugate Chemistry, 20:631–643.
96. McCarthy, J.R., and Weissleder, R., 2008. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Advanced Drug Delivery Reviews, 60:1241–1251.
97. Medina, O.P., Kairemo, K., Valtanen, H., Kangasniemi, A., Kaukinen, S., Ahonen, I., Permi, P., Annila, A., Sneck, M., Holopainen, J.M., Karonen, S.L., Kinnunen, P.K., and Koivunen, E., 2005. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide. Anticancer Research, 25:33–42.
98. Mier, W., Zitzmann, S., Kramer, S., Reed, J., Knapp, E.M., Altmann, A., Eisenhut, M., and Haberkorn, U., 2007. Influence of chelate conjugation on a newly identified tumor-targeting peptide. Journal of Nuclear Medicine, 48:1545–1552.
99. Mishani, E., Abourbeh, G., Eiblmaier, M., and Anderson, C.J., 2008. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Current Pharmaceutical Design, 14:2983–2998.
100. Moore, S.J., Olsen, M.J., Cochran, J.R., and Cochran, F.V., 2009. “ Cell surface display systems for protein engineering ”. In Protein Engineering and Design, Edited by:Park, S.J., and Cochran, J.R., 23–50. Boca Raton:CRC Press/Taylor and Francis.
101. Mori, T., 2004. Cancer-specific ligands identified from screening of peptide-display libraries. Current Pharmaceutical Design, 10:2335–2343.
102. Mukai, T., Suganuma, N., Soejima, K., Sasaki, J., Yamamoto, F., and Maeda, M., 2008. Synthesis of a ?-tetrapeptide analog as a mother compound for the development of matrix metalloproteinase-2-imaging agents. Chemical and Pharmaceutical Bulletin, 56:260–265.
103. Nahrendorf, M., Jaffer, F.A., Kelly, K.A., Sosnovik, D.E., Aikawa, E., Libby, P., and Weissleder, R., 2006. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation, 114:1504–1511.
104. Newton, J., and Deutscher, S., 2008. Phage peptide display. Handbook of Experimental Pharmacology, 185 (Pt 2):145–163.
105. Newton, J.R., and Deutscher, S., 2009. In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents. Methods in Molecular Biology, 504:275–290.
106. Newton, J.R., Kelly, K.A., Mahmood, U., Weissleder, R., and Deutscher, S., 2006. In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia, 8:772–780.
107. Newton, J.R., Miao, Y., Deutscher, S., and Quinn, T.P., 2007. Melanoma imaging with pretargeted bivalent bacteriophage. Journal of Nuclear Medicine, 48:429–436.
108. Newton-Northup, J.R., Figueroa, S.D., Quinn, T.P., and Deutscher, S., 2009. Bifunctional phage-based pretargeted imaging of human prostate carcinoma. Nuclear Medicine and Biology, 36:789–800.
109. Nishiyama, K., Takakusagi, Y., Kusayanagi, T., Matsumoto, Y., Habu, S., Kuramochi, K., Sugawara, F., Sakaguchi, K., Takahashi, H., Natsugari, H., and Kobayashi, S., 2009. Identification of trimannoside-recognizing peptide sequences from a T7 phage display screen using a QCM device. Bioorganic & Medicinal Chemistry, 17:195–202.
110. Nord, K., Gunneriusson, E., Ringdahl, J., Stahl, S., Uhlen, M., and Nygren, P.A., 1997. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nature Biotechnology, 15:772–777.
111. Nordberg, A., 2009. The future:new methods of imaging exploration in Alzheimer's disease. Frontiers of Neurology and Neuroscience, 24:47–53.
112. Nygren, P.A., 2008. Alternative binding proteins:affibody binding proteins developed from a small three-helix bundle scaffold. The FEBS Journal, 275:2668–2676.
113. Orlova, A., Feldwisch, J., Abrahmsen, L., and Tolmachev, V., 2007a. Affibody molecules for molecular imaging and therapy for cancer. Cancer Biotherapy and Radiopharmaceuticals, 22:573–584.
114. Orlova, A., Magnusson, M., Eriksson, T.L., Nilsson, M., Larsson, B., Hoiden-Guthenberg, I., Widstrom, C., Carlsson, J., Tolmachev, V., Stahl, S., and Nilsson, F.Y., 2006. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Research, 66:4339–4348.
115. Orlova, A., Tolmachev, V., Pehrson, R., Lindborg, M., Tran, T., Sandstrom, M., Nilsson, F.Y., Wennborg, A., Abrahmsen, L., and Feldwisch, J., 2007b. Synthetic affibody molecules:a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Research, 67:2178–2186.
116. Overoye-Chan, K., Koerner, S., Looby, R.J., Kolodziej, A.F., Zech, S.G., Deng, Q., Chasse, J.M., McMurry, T.J., and Caravan, P., 2008. EP-2104R:A fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. Journal of the American Chemical Society, 130:6025–6039.
117. Ozawa, M.G., Zurita, A., Dias-Neto, E., Nunes, D.N., Sidman, R.L., Gelovani, J.G., Arap, W., and Pasqualini, R., 2008. Beyond receptor expression levels:the relevance of target accessibility in ligand-directed pharmacodelivery systems. Trends in Cardiovascular Medicine, 18:126–132.
118. Pasqualini, R., and Ruoslahti, E., 1996. Organ targeting in vivo using phage display peptide libraries. Nature, 380:364–366.
119. Pepper, L.R., Cho, Y.K., Boder, E.T., and Shusta, E.V., 2008. A decade of yeast surface display technology:Where are we now?. Combinatorial Chemistry and High Throughput Screening, 11:127–134.
120. Perillo, N.L., Marcus, M.E., and Baum, L.G., 1998. Galectins:versatile modulators of cell adhesion, cell proliferation, and cell death. Journal of Molecular Medicine, 76:402–412.
121. Perkins, A.C., and Missailidis, S., 2007. Radiolabelled aptamers for tumour imaging and therapy. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 51:292–296.
122. Petrenko, V.A., 2008. Evolution of phage display:from bioactive peptides to bioselective nanomaterials. Expert Opinion on Drug Delivery, 5:825–836.
123. Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., and Ferrin, T.E., 2004. UCSF Chimera - A visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25:1605–1612.
124. Pilch, J., Brown, D.M., Komatsu, M., Jarvinen, T.A.H., Yang, M., Peters, D., Hoffman, R.M., and Ruoslahti, E., 2006. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proceedings of the National Academy of Sciences of the United States of America, 103:2800–2804.
125. Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., and Neri, D., 1998. Design and use of a phage display library:Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. Journal of Biological Chemistry, 273:21769–21776.
126. Pini, A., Giuliani, A., Ricci, C., Runci, Y., and Bracci, L., 2004. Strategies for the construction and use of peptide and antibody libraries displayed on phages. Current Protein and Peptide Science, 5:487–496.
127. Ploug, M., Ostergaard, S., Gardsvoll, H., Kovalski, K., Holst-Hansen, C., Holm, A., Ossowski, L., and Dano, K., 2001. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry, 40:12157–12168.
128. Presta, L.G., 2008. Molecular engineering and design of therapeutic antibodies. Current Opinion in Immunology, 20:460–470.
129. Rae, J., Creighton, C., Meck, J., Haddad, B., and Johnson, M., 2007. MDA-MB-435 cells are derived from M14 Melanoma cells--a loss for breast cancer, but a boon for melanoma research. Breast Cancer Research and Treatment, 104:13–19.
130. Rao, J., Dragulescu-Andrasi, A., and Yao, H., 2007. Fluorescence imaging in vivo:recent advances. Current Opinion in Biotechnology, 18:17–25.
131. 68Ga for PET imaging of HER2 expression. Journal of Nuclear Medicine, 50:1492–1499.
132. Reubi, J.C., and Maecke, H.R., 2008. Peptide-based probes for cancer imaging. Journal of Nuclear Medicine, 49:1735–1738.
133. Romer, J., Nielsen, B.S., and Ploug, M., 2004. The urokinase receptor as a potential target in cancer therapy. Current Pharmaceutical Design, 10:2359–2376.
134. Rosenberg, A., Griffin, K., Studier, F.W., McCormick, M., Berg, J., Novy, R., and Mierendorf, R., 1996. T7Select phage display system:a powerful new protein display system based on bacteriophage T7. inNovations, 6:1–6.
135. 76Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin. Journal of Nuclear Medicine, 48:1172–1179.
136. Rozinov, M.N., and Nolan, G.P., 1998. Evolution of peptides that modulate the spectral qualities of bound, small-molecule fluorophores. Chemistry and Biology, 5:713–728.
137. Ruoslahti, E., 2000. Targeting tumor vasculature with homing peptides from phage display. Seminars in Cancer Biology, 10:435–442.
138. 99mTc-labeled bacteriophage as a potential infection-specific imaging agent. Journal of Nuclear Medicine, 45:1201–1208.
139. Santimaria, M., Moscatelli, G., Viale, G.L., Giovannoni, L., Neri, G., Viti, F., Leprini, A., Borsi, L., Castellani, P., Zardi, L., Neri, D., and Riva, P., 2003. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clinical Cancer Research, 9:571–579.
140. Schmidt, M.M., and Wittrup, K.D., 2009. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Molecular Cancer Therapeutics, 8:2861–2871.
141. Segers, J., Laumonier, C., Burtea, C., Laurent, S., Elst, L.V., and Muller, R.N., 2007. From phage display to magnetophage, a new tool for magnetic resonance molecular imaging. Bioconjugate Chemistry, 18:1251–1258.
142. Sergeeva, A., Kolonin, M.G., Molldrem, J.J., Pasqualini, R., and Arap, W., 2006. Display technologies:Application for the discovery of drug and gene delivery agents. Advanced Drug Delivery Reviews, 58:1622–1654.
143. Sidhu, S.S., Ed (2005). Phage Display in Biotechnology and Drug Discovery. CRC Press/Taylor & Francis, Boca Raton.
144. Simberg, D., Duza, T., Park, J.H., Essler, M., Pilch, J., Zhang, L., Derfus, A. M., Yang, M., Hoffman, R. M., Bhatia, S., Sailor, M.J., and Ruoslahti, E., 2007. Biomimetic amplification of nanoparticle homing to tumors. Proceedings of the National Academy of Sciences of the United States of America, 104:932–936.
145. Slootweg, E.J., Keller, H.J., Hink, M.A., Borst, J.W., Bakker, J., and Schots, A., 2006. Fluorescent T7 display phages obtained by translational frameshift. Nucleic Acids Research, 34:e137
146. Smith, G.P., and Petrenko, V.A., 1997. Phage display. Chemical Reviews, 97:391–410.
147. Smith, G.P., and Scott, J.K., 1993. Libraries of peptides and proteins displayed on filamentous phage. Methods in Enzymology, 217:228–257.
148. Sosnovik, D.E., and Weissleder, R., 2007. Emerging concepts in molecular MRI. Current Opinion in Biotechnology, 18:4–10.
149. Souza, G.R., Christianson, D.R., Staquicini, F.I., Ozawa, M.G., Snyder, E.Y., Sidman, R.L., Miller, J.H., Arap, W., and Pasqualini, R., 2006. Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents. Proceedings of the National Academy of Sciences of the United States of America, 103:1215–1220.
150. Souza, G.R., Yonel-Gumruk, E., Fan, D., Easley, J., Rangel, R., Guzman-Rojas, L., Miller, J.H., Arap, W., and Pasqualini, R., 2008. Bottom-up assembly of hydrogels from bacteriophage and Au nanoparticles:the effect of cis- and trans-acting factors. PLoS ONE, 3:e2242
151. Sprague, J.E., Li, W.P., Liang, K., Achilefu, S., and Anderson, C.J., 2006. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nuclear Medicine and Biology, 33:227–237.
152. Spuentrup, E., Botnar, R., Wiethoff, A., Ibrahim, T., Kelle, S., Katoh, M., Ozgun, M., Nagel, E., Vymazal, J., Graham, P., Gunther, R., and Maintz, D., 2008. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent:initial results in patients. European Radiology, 18:1995–2005.
153. Steffen, A., Orlova, A., Wikman, M., Nilsson, F.Y., Stahl, S., Adams, G.P., Tolmachev, V., and Carlsson, J., 2006. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. European Journal of Nuclear Medicine and Molecular Imaging, 33:631–638.
154. Steffen, A.-C., Wikman, M., Tolmachev, V., Adams, G.P., Nilsson, F.Y., Stahl, S., and Carlsson, J.R., 2005. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biotherapy and Radiopharmaceuticals, 20:239–248.
155. Steiner, D., Forrer, P., and Pluckthun, A., 2008. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. Journal of Molecular Biology, 382:1211–1227.
156. Steiner, D., Forrer, P., Stumpp, M.T., and Pluckthun, A., 2006. Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display. Nature Biotechnology, 24:823–831.
157. Tavitian, B., and Haberkorn, U., 2009. Darwinian molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 36:1475–1482.
158. Thapa, N., Kim, S., So, I., Lee, B., Kwon, I., Choi, K., and Kim, I., 2008. Discovery of a phosphatidylserine-recognizing peptide and its utility in molecular imaging of tumour apoptosis. Journal of Cellular and Molecular Medicine, 12:1649–1660.
159. Tijink, B.M., Perk, L.R., Budde, M., Stigter-van Walsum, M., Visser, G.W.M., Kloet, R.W., Dinkelborg, L.M., Leemans, C.R., Neri, D., and van Dongen, G.A.M.S., 2009. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. European Journal of Nuclear Medicine and Molecular Imaging, 36:1235–1244.
160. Tolmachev, V., 2008. Imaging of HER-2 overexpression in tumors for guiding therapy. Current Pharmaceutical Design, 14:2999–3019.
161. Tolmachev, V., Friedman, M., Sandstrom, M., Eriksson, T.L., Rosik, D., Hodik, M., Stahl, S., Frejd, F., and Orlova, A., 2009a. Affibody molecules for epidermal growth factor receptor targeting in vivo:aspects of dimerization and labeling chemistry. Journal of Nuclear Medicine, 50:274–283.
162. Tolmachev, V., Mume, E., Sjoberg, S., Frejd, F., and Orlova, A., 2009b. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. European Journal of Nuclear Medicine and Molecular Imaging, 36:692–701.
163. Tolmachev, V., Orlova, A., Nilsson, F.Y., Feldwisch, J., Wennborg, A., and Abrahmsen, L., 2007. Affibody molecules:potential for in vivo imaging of molecular targets for cancer therapy. Expert Opinion on Biological Therapy, 7:555–568.
164. 99mTc-labeled anti-HER2 Affibody molecules. Bioconjugate Chemistry, 19:2568–2576.
165. Trepel, M., Pasqualini, R., and Arap, W., 2008. Screening phage-display peptide libraries for vascular targeted peptides. Methods in Enzymology, 445:83–106.
166. Van de Wiele, C., and Oltenfreiter, R., 2006. Imaging probes targeting matrix metalloproteinases. Cancer Biotherapy and Radiopharmaceuticals, 21:409–417.
167. Viti, F., Tarli, L., Giovannoni, L., Zardi, L., and Neri, D., 1999. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Research, 59:347–352.
168. Wang, H., Cai, W., Chen, K., Li, Z., Kashefi, A., He, L., and Chen, X., 2007a. A new PET tracer specific for vascular endothelial growth factor receptor 2. European Journal of Nuclear Medicine and Molecular Imaging, 34:2001–2010.
169. Wang, W., Ke, S., Kwon, S., Yallampalli, S., Cameron, A.G., Adams, K.E., Mawad, M.E., and Sevick-Muraca, E.M., 2007b. A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjugate Chemistry, 18:397–402.
170. Wang, W., Shao, R., Wu, Q., Ke, S., McMurray, J., Lang, F., Charnsangavej, C., Gelovani, J.G., and Li, C., 2009. Targeting gelatinases with a near-infrared fluorescent cyclic His-Try-Gly-Phe peptide. Molecular Imaging and Biology, 11:424–433.
171. Webster, J., Zhang, R., Gambhir, S., Cheng, Z., and Syud, F.A., 2009. Engineered twohelix small proteins for molecular recognition. ChemBioChem, 10:1293–1296.
172. Weissleder, R., and Pittet, M., 2008. Imaging in the era of molecular oncology. Nature, 452:580–589.
173. Weller, G.E.R., Wong, M.K.K., Modzelewski, R.A., Lu, E., Klibanov, A.L., Wagner, W.R., and Villanueva, F.S., 2005. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginineleucine. Cancer Research, 65:533–539.
174. Wikman, M., Steffen, A.C., Gunneriusson, E., Tolmachev, V., Adams, G.P., Carlsson, J., and Stahl, S., 2004. Selection and characterization of HER2/neu-binding affibody ligands. Protein Engineering, Design and Selection, 17:455–462.
175. Wu, A.M., 2009. Antibodies and antimatter:the resurgence of immuno-PET. Journal of Nuclear Medicine, 50:2–5.
176. Ye, F., Jeong, E.K., Jia, Z., Yang, T., Parker, D., and Lu, Z.R., 2008. A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjugate Chemistry, 19:2300–2303.
177. Zanuy, D., Curco, D., Nussinov, R., and Aleman, C., 2009. Influence of the dye presence on the conformational preferences of CREKA, a tumor homing linear pentapeptide. Peptide Science, 92:83–93.
178. Zhao, P., Grabinski, T., Gao, C., Skinner, R.S., Giambernardi, T., Su, Y., Hudson, E., Resau, J., Gross, M., Vande Woude, G.F., Hay, R., and Cao, B., 2007. Identification of a met-binding peptide from a phage display library. Clinical Cancer Research, 13:6049–6055.
179. Zhou, Y., Drummond, D.C., Zou, H., Hayes, M.E., Adams, G.P., Kirpotin, D.B., and Marks, J.D., 2007. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. Journal of Molecular Biology, 371:934–947.
180. Zitzmann, S., Kramer, S., Mier, W., Hebling, U., Altmann, A., Rother, A., Berndorff, D., Eisenhut, M., and Haberkorn, U., 2007. Identification and evaluation of a new tumor cell-binding peptide, FROP-1. Journal of Nuclear Medicine, 48:965–972.
181. Zou, J., Dickerson, M.T., Owen, N.K., Landon, L., and Deutscher, S., 2004. Biodistribution of filamentous phage peptide libraries in mice. Molecular Biology Reports, 31:121–129.
182. Zou, J., Glinsky, V.V., Landon, L., Matthews, L., and Deutscher, S., 2005. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasisassociated cancer cell adhesion. Carcinogenesis, 26:309–318.